Gastroenterology
Volume 138, Issue 3 , Pages 854-869, March 2010

History, Molecular Mechanisms, and Endoscopic Treatment of Barrett's Esophagus

  • Stuart Jon Spechler

      Affiliations

    • VA North Texas Healthcare System and The University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationReprint requests Address requests for reprints to: Stuart Jon Spechler, MD, Division of Gastroenterology, Dallas VA Medical Center, 4500 South Lancaster Road, Dallas, Texas 75216. fax: (214) 857-1571
    • ,
  • Rebecca C. Fitzgerald

      Affiliations

    • MRC Cancer Cell Unit, Hutchison-MRC Research Centre, Cambridge, England
    • ,
  • Ganapathy A. Prasad

      Affiliations

    • Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota
    • ,
  • Kenneth K. Wang

      Affiliations

    • Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota

Received 3 December 2009; accepted 11 January 2010. published online 18 January 2010.

John P. Lynch and David C. Metz, Section Editors

This report is an adjunct to the American Gastroenterological Association Institute's medical position statement and technical review on the management of Barrett's esophagus, which will be published in the near future. Those documents will consider a number of broad questions on the diagnosis, clinical features, and management of patients with Barrett's esophagus, and the reader is referred to the technical review for an in-depth discussion of those topics. In this report, we review historical, molecular, and endoscopic therapeutic aspects of Barrett's esophagus that are of interest to clinicians and researchers.

Keywords: Gastroesophageal Reflux, Esophageal Neoplasms, Gene Expression Regulation

Abbreviations used in this paper: BMP, bone morphogenetic protein, EMR, endoscopic mucosal resection, GERD, gastroesophageal reflux disease, LOH, loss of heterozygosity, PDT, photodynamic therapy, RFA, radiofrequency ablation

 

 Conflicts of interest The authors disclose no conflicts.

 Funding This work was supported by the Office of Medical Research, Department of Veterans Affairs and the National Institutes of Health (R01-CA134571). Dr Spechler receives research support from AstraZeneca, Takeda Pharmaceuticals, Inc, and BARRX Medical, Inc. Dr Spechler is a consultant for Procter & Gamble and Xenoport. Dr Wang received NIH grants R01CA097048, R01CA111603, and R21CA122426. In addition, Dr Wang receives research support from Mayo Foundation, BARRX Medical, Inc, Axcan Pharma, Olympus and Fujinon. Dr Prasad receives research support from AstraZeneca, Takeda, and the Mayo Foundation. Dr Fitzgerald receives research support from the Medical Research Council (MRC).

PII: S0016-5085(10)00018-1

doi:10.1053/j.gastro.2010.01.002

Gastroenterology
Volume 138, Issue 3 , Pages 854-869, March 2010

Article Tools

* Image Usage & Resolution